Higher incidence of delayed methotrexate clearance in pediatric acute lymphoblastic leukemia patients treated with imatinib

Background: Pediatric patients with Philadelphia chromosome positive (Ph+) or ABL-class fusion positive acute lymphoblastic leukemia (ALL) are currently treated with the tyrosine kinase inhibitor (TKI) imatinib added to a chemotherapy backbone that also contains several courses of high-dose methotre...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Inge M. van der Sluis, Nikita D. van Dijk, Leiah J. Brigitha, Freya M. Steinhauer, Rob Pieters
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2023-12-01
Edice:	EJC Paediatric Oncology
Témata:	Acute lymphoblastic leukemia Imatinib High-dose methotrexate Clearance Pediatric
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2772610X23001113
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!